Literature DB >> 19539961

[B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA pronostic indexes].

Ana Pilar González Rodríguez1, Esther González García, Carmen Fernández Alvarez, Ana Julia González Huerta, Segundo González Rodríguez.   

Abstract

BACKGROUND AND
OBJECTIVE: The clinical course of B-chronic lymphocytic leukemia (B-CLL) patients is highly heterogeneous and the prognosis of these patients is difficult to predict. In this study, we analysed two new prognostic indexes proposed by the MDACC and GIMEMA group in a random population of B-CCL patients. PATIENTS AND METHODS: A follow up study of a cohort of patients was carried out. 265 B-CLL patients diagnosed in the Area Sanitaria de Gijón during 10 years (1997-2007) were analysed in this study. The overall survival of the patients was analysed by the Rai and Binet staging systems and the prognostic indexes proposed by the MDACC and GIMEMA group.
RESULTS: The crude rate was 8.99 per 100.000 populations for year and the adjusted-age rate was 3.47 per 100.000 populations for year. The distribution of patients based on the MDACC index was: 31.4% had low risk, 62% had intermediate risk and 6.6% had high risk. The percentage of 5- and 10-years survival probabilities were 87% and 73% for low risk, 75% and 49% for intermediate risk and 29% and 16% of high risk. The GIMEMA index was unable to predict the overall survival in our patients.
CONCLUSIONS: The rates of B-CLL are higher in our population than previously described, which is probably caused by an earlier diagnosis. Our results indicate that the MDACC prognostic index predicted the overall survival and the prognosis of a random population of patients better than the classical staging systems. The simplicity and utility of this prognostic index may help clinicians in clinical decision and therapeutical management.

Entities:  

Mesh:

Year:  2009        PMID: 19539961     DOI: 10.1016/j.medcli.2008.09.046

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  5 in total

1.  IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.

Authors:  Pietro Bulian; Davide Rossi; Francesco Forconi; Giovanni Del Poeta; Francesco Bertoni; Emanuele Zucca; Marco Montillo; Gabriele Pozzato; Giovanni D'Arena; Dimitar G Efremov; Roberto Marasca; Francesco Lauria; Gianluca Gaidano; Valter Gattei; Luca Laurenti
Journal:  J Transl Med       Date:  2012-01-30       Impact factor: 5.531

2.  Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.

Authors:  Luis Felipe Casado; Amparo Burgos; Eva González-Haba; Javier Loscertales; Tania Krivasi; Javier Orofino; Carlos Rubio-Terres; Darío Rubio-Rodríguez
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

3.  The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index.

Authors:  Carolina Muñoz-Novas; María Poza-Santaella; Isabel González-Gascón Y Marín; María Hernández-Sánchez; Ana-Eugenia Rodríguez-Vicente; María-Stefania Infante; Cecilia Heras; María-Ángeles Foncillas; Karen Marín; Jesús-María Hernández-Rivas; José-Ángel Hernández
Journal:  Biomed Res Int       Date:  2018-03-15       Impact factor: 3.411

4.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31

Review 5.  Lenalidomide and chronic lymphocytic leukemia.

Authors:  Ana Pilar González-Rodríguez; Angel R Payer; Andrea Acebes-Huerta; Leticia Huergo-Zapico; Monica Villa-Alvarez; Esther Gonzalez-García; Segundo Gonzalez
Journal:  Biomed Res Int       Date:  2013-09-19       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.